Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
AiCuris AG
Allecra Therapeutics GmbH
Antabio SAS
Aridis Pharmaceuticals Inc
Biolytx Pharmaceuticals Corp
Bioversys AG
Cellular Biomedicine Group Inc
Centauri Therapeutics Ltd
Clarametyx Biosciences Inc
ContraFect Corp
Cumberland Pharmaceuticals Inc
CytaCoat AB
Destiny Pharma Plc
Dong-A Socio Holdings Co Ltd
Eldec Pharmaceuticals Inc
Entasis Therapeutics Holdings Inc
Evotec SE
GangaGen Biotechnologies Pvt Ltd
Helperby Therapeutics Group Ltd
Hoth Therapeutics Inc
Hypo-Stream Ltd
La Jolla Pharmaceutical Company
Meiji Seika Pharma Co Ltd
Merck & Co Inc
briva Therapeutics Plc
Nosopharm SAS
Omnix Medical Ltd
Peptineo
Pfizer Inc
Pherecydes Pharma SA
Phico Therapeutics Ltd
Pulmobiotics SL
Qilu Pharmaceutical Co Ltd
Revagenix Inc
Shionogi & Co Ltd
Spero Therapeutics Inc
Spexis AG
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
VetoRx Pharmaceuticals Inc
Wockhardt Ltd
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam + aztreom) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(avibactam sodium + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + taniborbactam hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
ABX-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AlloJoin - Drug Profile
Product Description
Mechanism Of Action
History of Events
arbekacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Ventilator Associated Pneumonia - Drug Profile
Product Description
Mechanism Of Action
BP-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-370 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CMTX-101 - Drug Profile
Product Description
Mechanism Of Action
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELD-607 - Drug Profile
Product Description
Mechanism Of Action
History of Events
eravacycline dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
FL-058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
HT-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HY-010B3 - Drug Profile
Product Description
Mechanism Of Action
HY-011B4 - Drug Profile
Product Description
Mechanism Of Action
HY-012B5 - Drug Profile
Product Description
Mechanism Of Action
HY-015B12 - Drug Profile
Product Description
Mechanism Of Action
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
levodifloxacin - Drug Profile
Product Description
Mechanism Of Action
MEMANT-3310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
murepavadin - Drug Profile
Product Description
Mechanism Of Action
History of Events
cubactam - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOSO-2G - Drug Profile
Product Description
Mechanism Of Action
History of Events
OMN-6 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Paecin - Drug Profile
Product Description
Mechanism Of Action
History of Events
panobacumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides for Complicated Skin and Skin Structure Infections and Hospital Acquired Pneumonia (HAP) - Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-1231 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Proteins to Inhibit Peptidoglycan (Murein) for Bacterial Infections, Cystic Fibrosis, Hospital Acquired Pneumonia and Diabetic Foot Infection - Drug Profile
Product Description
Mechanism Of Action
History of Events
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
rifabutin - Drug Profile
Product Description
Mechanism Of Action
History of Events
SASPjectPT-3.9 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Hospital Acquired Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP) - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Hospital-Acquired Pneumonia, Intra-Abdomil and Uriry Tract Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
SPR-206 - Drug Profile
Product Description
Mechanism Of Action
History of Events
suvratoxumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
History of Events
telavancin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
XF-70 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2021: Vetorx Pharmaceuticals provides update on Cefepime-Taniborbactam
Jun 07, 2021: The results of a preclinical trial demonstrating the benefits of inhaled Pherecydes Pharma phages in treating ventilation-associated pneumonia have been published in the prestigious British Jourl of Pharmacology
Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials
Apr 19, 2021: Phico Therapeutics awarded up to $18.2 million USD CARB-X funding to advance SASPject antibacterial therapy through phase 1 clinical trials
Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicil product Recarbrio
Oct 16, 2020: CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicil product Recarbrio
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicil product Zavicefta
Sep 18, 2020: AstraZeneca receives CHMP positive opinion recommending a change to the terms of the marketing authorisation for the medicil product Zavicefta
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Jun 25, 2020: CHMP recommended extensions of indication for Zavicefta
Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jun 04, 2020: FDA approves antibiotic to treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jun 01, 2020: FDA accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA (cefiderocol) for the Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia
May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) desigtion for MEM-ANT3310, a novel broad-spectrum combition therapy targeting WHO’s priority pathogens
May 06, 2020: Antabio receives FDA qualified infectious disease product (QIDP) desigtion for MEM-ANT3310, a novel broad-spectrum combition therapy targeting WHO’s priority pathogens
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by AiCuris AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Allecra Therapeutics GmbH, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Antabio SAS, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Biolytx Pharmaceuticals Corp, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Bioversys AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Cellular Biomedicine Group Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Clarametyx Biosciences Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by ContraFect Corp, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Cumberland Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Plc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Eldec Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Evotec SE, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by GangaGen Biotechnologies Pvt Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Helperby Therapeutics Group Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Hoth Therapeutics Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Hypo-Stream Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by La Jolla Pharmaceutical Company, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics Plc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Nosopharm SAS, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Omnix Medical Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Peptineo, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pfizer Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pherecydes Pharma SA, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Phico Therapeutics Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Pulmobiotics SL, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Revagenix Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Spero Therapeutics Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Spexis AG, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by TGV-Inhalonix Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Therapeutic Systems Research Laboratories Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by VenatoRx Pharmaceuticals Inc, 2022
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, 2022
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..1)
Hospital Acquired Pneumonia (HAP) - Dormant Projects, 2022 (Contd..2)
Hospital Acquired Pneumonia (HAP) - Discontinued Products, 2022